Stefano Caruso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stefano Caruso has a total of 533 co-authors. Here are the top co-authors by number of shared publications:
- Jessica Zucman-Rossi
Centre de Recherche des Cordeliers 1 Paris, France
65 shared publications Julien Calderaro
29 shared publicationsGiuliana Amaddeo
26 shared publicationsValérie Paradis
26 shared publicationsAlain Luciani
25 shared publicationsAurélie Beaufrère
24 shared publications
Latest Publications
- Open Access
- 30 January 2026
- Published by S. Karger AG in Liver Cancer
- p. 1-13
Machine Learning Models for Disease-Free Survival Analysis after Liver Resection for Hepatocellular Carcinoma: A Multicentric French Collaborative Study
Introduction: Liver resection (LR) is a potentially curative treatment of hepatocellular carcinoma (HCC), but early recurrence rates remain high reaching as high as 70%. Accurate prediction of disease-free survival (DFS) after LR is crucial to optimize patients’ selection for clinical trials evaluating adjuvant strategies. This study assessed machine learning (ML) models for predicting DFS after LR for HCC. Methods: A total of 663 patients who underwent LR between 2010 and 2020 in 3 French HPB referral centers were analyzed. Three ML models – random survival forest (RSF), gradient boosting survival (GBS), and fast survival support vector machine (FSSVM) – were compared with the Cox proportional hazards regression model. Model performance was assessed using C-index and time-dependent area under the curve (AUC). External validation was performed using an independent cohort from a fourth center. Statistical comparisons between models were conducted using paired t tests. Results: After a median follow up of 52 months, recurrence occurred in 43% of patients and median DFS was 15 months. In the training cohort, RSF achieved the highest discrimination (C-index = 0.721 ± 0.027) and predictive accuracy (AUC = 0.768 ± 0.039) among the four evaluated models. Cox, GBS, and FSSVM showed comparable performance (C-index = 0.684–0.699; AUC = 0.718–0.745). Paired t tests demonstrated that RSF significantly outperformed Cox for both C-index (p = 0.023) and AUC (p = 0.039). In the external validation cohort, all ML models outperformed Cox regression, with RSF showing the highest performance (C-index 0.817, AUC 0.863), suggesting strong generalizability. Conclusions: RSF significantly improved DFS prediction compared with Cox regression and yielded the best discriminatory performance in both training and external validation cohorts. These findings highlight the value of ML-based survival models, particularly RSF, for enhancing individualized postoperative prognostication and refining patient selection for clinical trials evaluating adjuvant treatment to surveillance after LR for HCC.
- 30 January 2026
- Published by S. Karger AG in Liver Cancer
- p. 1-13
Open AccessMachine Learning Models for Disease-Free Survival Analysis after Liver Resection for Hepatocellular Carcinoma: A Multicentric French Collaborative Study
Introduction: Liver resection (LR) is a potentially curative treatment of hepatocellular carcinoma (HCC), but early recurrence rates remain high reaching as high as 70%. Accurate prediction of disease-free survival (DFS) after LR is crucial to optimize patients’ selection for clinical trials evaluating adjuvant strategies. This study assessed machine learning (ML) models for predicting DFS after LR for HCC. Methods: A total of 663 patients who underwent LR between 2010 and 2020 in 3 French HPB referral centers were analyzed. Three ML models – random survival forest (RSF), gradient boosting survival (GBS), and fast survival support vector machine (FSSVM) – were compared with the Cox proportional hazards regression model. Model performance was assessed using C-index and time-dependent area under the curve (AUC). External validation was performed using an independent cohort from a fourth center. Statistical comparisons between models were conducted using paired t tests. Results: After a median follow up of 52 months, recurrence occurred in 43% of patients and median DFS was 15 months. In the training cohort, RSF achieved the highest discrimination (C-index = 0.721 ± 0.027) and predictive accuracy (AUC = 0.768 ± 0.039) among the four evaluated models. Cox, GBS, and FSSVM showed comparable performance (C-index = 0.684–0.699; AUC = 0.718–0.745). Paired t tests demonstrated that RSF significantly outperformed Cox for both C-index (p = 0.023) and AUC (p = 0.039). In the external validation cohort, all ML models outperformed Cox regression, with RSF showing the highest performance (C-index 0.817, AUC 0.863), suggesting strong generalizability. Conclusions: RSF significantly improved DFS prediction compared with Cox regression and yielded the best discriminatory performance in both training and external validation cohorts. These findings highlight the value of ML-based survival models, particularly RSF, for enhancing individualized postoperative prognostication and refining patient selection for clinical trials evaluating adjuvant treatment to surveillance after LR for HCC.
- Open Access
- 11 December 2025
- Published by S. Karger AG in Liver Cancer
- p. 1-18
Feasibility and Effectiveness of Liver Transplantation following Immunotherapy in Patients with Hepatocellular Carcinoma
Introduction: Immunotherapy is an attractive strategy for downstaging/bridging treatment of hepatocellular carcinoma (HCC) before liver transplantation (LT). This multicentre study reports the feasibility and effectiveness of LT following immunotherapy in a French HCC cohort. Methods: Clinical, biological, and radiological data were collected at the start and end of immunotherapy, and before LT. Outcomes were evaluated through radiological response post-immunotherapy, recurrence risk (R3-alpha-fetoprotein [AFP] score) on explanted livers, and post-LT complications, aiming to assess primary LT success, overall and disease-free survival. Results: Twenty-one HCC patients (17 males; median age 62 years [57–64]) were included in the study. Fourteen (66.7%) patients were BCLC-B, and sixteen (76.2%) received atezolizumab/bevacizumab (median 8.5 cycles [4.7–14]). At the end of immunotherapy, 57.1% met Milan-in criteria, and 95.2% had AFP score ≤2 (p = 0.002). The median interval from last immunotherapy to LT was 5.1 (2.7–9.3) months. All but 3 patients received standard immunosuppression. Explant pathology showed residual tumours in 71.4%, with 47.6% at high recurrence risk according to R3-AFP score. Two patients experienced allograft rejection, and one (4.8%) had HCC recurrence post-LT. Early adverse events occurred in 6 (28.5%) patients, leading to 5 (23.8%) deaths. At 12 months, 71.4% were alive without HCC recurrence. Lower overall survival was linked to pre-LT Child-Pugh B class, absence of prior HCC treatment, fewer than 5 immunotherapy cycles, and early post-LT complications. Conclusion: LT following immunotherapy is feasible in selected HCC patients, although caution is warranted due to the potential but manageable rejection risk. However, high early mortality warrants further investigation in larger prospective series.
- 11 December 2025
- Published by S. Karger AG in Liver Cancer
- p. 1-18
Open AccessFeasibility and Effectiveness of Liver Transplantation following Immunotherapy in Patients with Hepatocellular Carcinoma
Introduction: Immunotherapy is an attractive strategy for downstaging/bridging treatment of hepatocellular carcinoma (HCC) before liver transplantation (LT). This multicentre study reports the feasibility and effectiveness of LT following immunotherapy in a French HCC cohort. Methods: Clinical, biological, and radiological data were collected at the start and end of immunotherapy, and before LT. Outcomes were evaluated through radiological response post-immunotherapy, recurrence risk (R3-alpha-fetoprotein [AFP] score) on explanted livers, and post-LT complications, aiming to assess primary LT success, overall and disease-free survival. Results: Twenty-one HCC patients (17 males; median age 62 years [57–64]) were included in the study. Fourteen (66.7%) patients were BCLC-B, and sixteen (76.2%) received atezolizumab/bevacizumab (median 8.5 cycles [4.7–14]). At the end of immunotherapy, 57.1% met Milan-in criteria, and 95.2% had AFP score ≤2 (p = 0.002). The median interval from last immunotherapy to LT was 5.1 (2.7–9.3) months. All but 3 patients received standard immunosuppression. Explant pathology showed residual tumours in 71.4%, with 47.6% at high recurrence risk according to R3-AFP score. Two patients experienced allograft rejection, and one (4.8%) had HCC recurrence post-LT. Early adverse events occurred in 6 (28.5%) patients, leading to 5 (23.8%) deaths. At 12 months, 71.4% were alive without HCC recurrence. Lower overall survival was linked to pre-LT Child-Pugh B class, absence of prior HCC treatment, fewer than 5 immunotherapy cycles, and early post-LT complications. Conclusion: LT following immunotherapy is feasible in selected HCC patients, although caution is warranted due to the potential but manageable rejection risk. However, high early mortality warrants further investigation in larger prospective series.
- 20 September 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 190, S37
KIR3DL2 also represents a novel therapeutic target in non-cutaneous aggressive systemic peripheral T-cell lymphomas
- 20 September 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 190, S37
KIR3DL2 also represents a novel therapeutic target in non-cutaneous aggressive systemic peripheral T-cell lymphomas
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer
All 17 supplementary figures and legends in a pdf file
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer
All 17 supplementary figures and legends in a pdf file
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer
All 11 supplementary tables in an excel file
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer
All 11 supplementary tables in an excel file
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer
All 11 supplementary tables in an excel file
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer
All 11 supplementary tables in an excel file
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer
All 17 supplementary figures and legends in a pdf file
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer
All 17 supplementary figures and legends in a pdf file
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer
Pediatric liver cancers (PLC) comprise diverse diseases affecting infants, children, and adolescents. Despite overall good prognosis, PLCs display heterogeneous response to chemotherapy. Integrated genomic analysis of 126 pediatric liver tumors showed a continuum of driver mechanisms associated with patient age, including new targetable oncogenes. In 10% of patients with hepatoblastoma, all before three years old, we identified a mosaic premalignant clonal expansion of cells altered at the 11p15.5 locus. Analysis of spatial and longitudinal heterogeneity revealed an important plasticity between “hepatocytic,” “liver progenitor,” and “mesenchymal” molecular subgroups of hepatoblastoma. We showed that during chemotherapy, “liver progenitor” cells accumulated massive loads of cisplatin-induced mutations with a specific mutational signature, leading to the development of heavily mutated relapses and metastases. Drug screening in PLC cell lines identified promising targets for cisplatin-resistant progenitor cells, validated in mouse xenograft experiments. These data provide new insights into cisplatin resistance mechanisms in PLC and suggest alternative therapies.Significance:PLCs are deadly when they resist chemotherapy, with limited alternative treatment options. Using a multiomics approach, we identified PLC driver genes and the cellular phenotype at the origin of cisplatin resistance. We validated new treatments targeting these molecular features in cell lines and xenografts.This article is highlighted in the In This Issue feature, p. 2355
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer
Pediatric liver cancers (PLC) comprise diverse diseases affecting infants, children, and adolescents. Despite overall good prognosis, PLCs display heterogeneous response to chemotherapy. Integrated genomic analysis of 126 pediatric liver tumors showed a continuum of driver mechanisms associated with patient age, including new targetable oncogenes. In 10% of patients with hepatoblastoma, all before three years old, we identified a mosaic premalignant clonal expansion of cells altered at the 11p15.5 locus. Analysis of spatial and longitudinal heterogeneity revealed an important plasticity between “hepatocytic,” “liver progenitor,” and “mesenchymal” molecular subgroups of hepatoblastoma. We showed that during chemotherapy, “liver progenitor” cells accumulated massive loads of cisplatin-induced mutations with a specific mutational signature, leading to the development of heavily mutated relapses and metastases. Drug screening in PLC cell lines identified promising targets for cisplatin-resistant progenitor cells, validated in mouse xenograft experiments. These data provide new insights into cisplatin resistance mechanisms in PLC and suggest alternative therapies.Significance:PLCs are deadly when they resist chemotherapy, with limited alternative treatment options. Using a multiomics approach, we identified PLC driver genes and the cellular phenotype at the origin of cisplatin resistance. We validated new treatments targeting these molecular features in cell lines and xenografts.This article is highlighted in the In This Issue feature, p. 2355
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma
Long noncoding RNAs (lncRNA) are emerging as key players in cancer as parts of poorly understood molecular mechanisms. Here, we investigated lncRNAs that play a role in hepatocellular carcinoma (HCC) and identified NIHCOLE, a novel lncRNA induced in HCC with oncogenic potential and a role in the ligation efficiency of DNA double-stranded breaks (DSB). NIHCOLE expression was associated with poor prognosis and survival of HCC patients. Depletion of NIHCOLE from HCC cells led to impaired proliferation and increased apoptosis. NIHCOLE deficiency led to accumulation of DNA damage due to a specific decrease in the activity of the nonhomologous end-joining (NHEJ) pathway of DSB repair. DNA damage induction in NIHCOLE-depleted cells further decreased HCC cell growth. NIHCOLE was associated with DSB markers and recruited several molecules of the Ku70/Ku80 heterodimer. Further, NIHCOLE putative structural domains supported stable multimeric complexes formed by several NHEJ factors including Ku70/80, APLF, XRCC4, and DNA ligase IV. NHEJ reconstitution assays showed that NIHCOLE promoted the ligation efficiency of blunt-ended DSBs. Collectively, these data show that NIHCOLE serves as a scaffold and facilitator of NHEJ machinery and confers an advantage to HCC cells, which could be exploited as a targetable vulnerability.Significance:This study characterizes the role of lncRNA NIHCOLE in DNA repair and cellular fitness in HCC, thus implicating it as a therapeutic target.See related commentary by Barcena-Varela and Lujambio, p. 4899
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma
Long noncoding RNAs (lncRNA) are emerging as key players in cancer as parts of poorly understood molecular mechanisms. Here, we investigated lncRNAs that play a role in hepatocellular carcinoma (HCC) and identified NIHCOLE, a novel lncRNA induced in HCC with oncogenic potential and a role in the ligation efficiency of DNA double-stranded breaks (DSB). NIHCOLE expression was associated with poor prognosis and survival of HCC patients. Depletion of NIHCOLE from HCC cells led to impaired proliferation and increased apoptosis. NIHCOLE deficiency led to accumulation of DNA damage due to a specific decrease in the activity of the nonhomologous end-joining (NHEJ) pathway of DSB repair. DNA damage induction in NIHCOLE-depleted cells further decreased HCC cell growth. NIHCOLE was associated with DSB markers and recruited several molecules of the Ku70/Ku80 heterodimer. Further, NIHCOLE putative structural domains supported stable multimeric complexes formed by several NHEJ factors including Ku70/80, APLF, XRCC4, and DNA ligase IV. NHEJ reconstitution assays showed that NIHCOLE promoted the ligation efficiency of blunt-ended DSBs. Collectively, these data show that NIHCOLE serves as a scaffold and facilitator of NHEJ machinery and confers an advantage to HCC cells, which could be exploited as a targetable vulnerability.Significance:This study characterizes the role of lncRNA NIHCOLE in DNA repair and cellular fitness in HCC, thus implicating it as a therapeutic target.See related commentary by Barcena-Varela and Lujambio, p. 4899
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma
Supplementary Materials and Methods
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma
Supplementary Materials and Methods